1789 TT

ScinoPharm Investor Conference

— 2024 03 15

ScinoPharm Taiwan

Disclaimer

This material has been prepared by ScinoPharm Taiwan, Ltd. (“ScinoPharm”).

Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. ScinoPharm is under no obligation to update or keep current the information contained herein. The **information contained** in this presentation **is** ScinoPharm’s **confidential** information.

Any disclosure, copying, distribution or any action taken or omitted to be taken in reliance on it is prohibited and may be unlawful.

No representation or warranty, express or implied, is or **will be made** in or in relation to, and no responsibility or liability is or will be accepted by the Company **as to**, the **accuracy or completeness** of this material and any liability therefore is hereby expressly disclaimed.

Statements made in this material include forward-looking statements, which include, without limitation, statements about the issues, plans and expectations of ScinoPharm. Without limiting the foregoing, statements including the words “believes”, “anticipates”, “plans”, “expects” and similar expressions are also forward-looking statements. Forward-looking statements reflect, among other things, management’s plans and objectives for future operations, current views with respect to future events and future economic performances and projections of various financial items. **These forward-looking statements involve known and unknown risks**, uncertainties and other factors **which may cause actual results to differ materially from those implied** by such forward-looking statements.

Agenda

01 Overview

02 Business Update

03 2024 Product Approval Plan

04 Financial Performance



Overview

I. Outlook for DP sector and Chinese subsidiary is optimistic, indicating a buildup of momentum

- The inaugural injectable CMO has met its commercial production goal and officially generated revenue, signaling the onset of progress in the development of the Drug Product sector
- Changshu has turned losses into profits, continuously playing a crucial role in collaboration within the group and catering to the Chinese market
- The necessary investments for getting regulatory approvals and the optimization of production facilities have been gradually completed, continuously enhancing the overall commercial competitiveness
- 2023 consolidated revenue was US$102.14mil, yoy -6.7%, or NT$3,186mil, yoy -2.4%; NPAT was NT$287mil, yoy -18.7%, with NPAT margin of 9%

II. Assure the bedrock of generic API and pursue substantive growth

- Drive systematic production planning and expand the range of core products to assure the bedrock of generic API business
- Optimize cost competitiveness and leverage flexible pricing to support formulation customers in strengthening market penetration and market share, keeping on creating sales opportunities for API products
- Continuously expand the portfolio of DMFs to enrich the scale of generic API pipelines
- Enhance internal coordination for sales/production planning, make good use of R&D capabilities, and continue to expand CDMO services for new drug clients

III. Fully augment DP business and implement vertical integration

- Strengthen internal learning and integrate resources, proactively tackle regulatory reviews for drug products, aiming to accelerate regulatory approvals
- Focus on complex injectables and peptide combination drugs, leverage the experience and advantage of API synthesis, and continuously venture into new product development to seize business opportunities
- Successfully establish the foundation for commercialized injectable CMO, further enlarge service contents, product items and new clientele, while simultaneously optimize production capabilities, to construct a comprehensive integrated service
- Collaborate with partners to spread projects in potential 505b2 drugs, seizing opportunities in formulation development



Business Updates

2023 Approved Products

Type	Product	Region	Indication	Brand Marketer
Generic API	Bimatoprost	CN ✓	Glaucoma	Allergan
Generic API	Galantamine HBr	CN ✓	Alzheimer's disease	Janssen
CDMO API	Ganaxolone	EU ✓	Genetic epilepsy	Marinus
CDMO API	Eflornithine	US ✓	Pediatric neuroblastoma	Post-marketing disclosure
Intermediate for CDMO API	Sotagliflozin	US ✓	Heart failure	Lexicon
Generic Drug	Bortezomib	US ✓	Multiple myeloma	Takeda

✓ : Approved

Optimize Generic API Portfolio

Generic API Portfolio



* Two oncology products added in 2023

Expand CDMO Business

CDMO Business Status



* One phase II product added in 2023; one phase III CDMO product was approved by US FDA in Dec., 2023 and business status changed from Phase III to Commercial

As of 2024/01/31

Vertically Integrated Injectable

In-House Drug Product Status



*Responded to FDA CRL

Vertically Integrated Injectable

Drug Product Collaboration

505(b)(2) Collaboration for Non-Small Cell Lung Cancer	Launched in US by customer
ANDA Collaboration for Non-Small Cell Lung Cancer	Launched in US/EU by customer
ANDA Collaboration for Multiple Myeloma	Launched in the US/EU and submitted to other regions by customer
In-house Prefilled Syringe Product	Exclusive partnership in US, ANDA under US FDA review
Contract Manufacturing of Oncology Injectable	Routine dispatch for commercial supply in the US
Two In-house Cartridge Products	Exclusive partnership in US, ANDA under US FDA review

China Market

- 4 CFDI on-site inspections completed in Changshu site to facilitate China market growth

	Product	Approval	Indication	Market
2020.09	Sodium Phenylbutyrate*	2021.05	Urea cycle disorders	Orphan disease medicine
2021.02	Donafenib	2021.06	Advanced liver cancer Thyroid cancer	c. RMB 600 million
2021.06	Bimatoprost	2023.02	Glaucoma	Prostaglandin drug products c. RMB 1 billion
2022.11	Azilsartan	2022.09	Hypertension	c. RMB 100 million

* Customer's clinical trial for new indication in progress

- Changshu site expects more inspections in 2024



2024 Product Approval Plan

2024 Product Approval Plan

Type	Product	Region	Indication	Brand Marketer
Generic API	Cladrbine	CN	Multiple Sclerosis	Merck
Generic API	Olaparib	CN	Cancer	AstraZeneca
Generic API	Exemestane	CN	Breast Cancer	Pfizer
Generic API	Azacitidine	EU	Myelodysplastic syndromes	Celgene
Generic API	Dantrolene Na	EU	Malignant Hyperthermia	Eagles
CDMO API	Eflornithine	US/EU	Familial Adenomatous Polyposis	Post-marketing Disclosure
CDMO API	Eflornithine	EU	Neuroblastoma	Post-marketing Disclosure
Generic Drug	Clofarabine	US	Acute Lymphoblastic Leukemia	Genzyme



Financial Performance

Sales Distribution – By Business





Unit: USD/M

	Generic API	CDMO	Drug Product
FY 2023 Sales	62.9	25.1	14.1
YoY	-12.2%	7.8%	-2.4%

Sales Distribution – By Indication





Unit: USD/M

	Oncology	CNS	Others
FY 2023 Sales	63.5	22.1	16.5
YoY	-11.7%	-5.9%	18.0%

Sales Distribution – By Region





Unit: USD/M

	US & Canada	EU	Japan	India	China	Others
FY 2023 Sales	15.9	22.1	16.9	16.9	15.8	14.5
YoY	-33.0%	11.5%	-19.0%	-12.5%	43.9%	-1.4%

Consolidated Income Statement

NTD Million except for EPS	2023		YoY	2022	
Revenue	3,186	100%	-2%	3,264	100%
Gross Profit	1,216	38%	-3%	1,251	38%
Operating Expenses	(901)	-28%	7%	(845)	-26%
Operating Profit	314	10%	-22%	405	12%
Net Profit before Tax	349	11%	-20%	438	13%
Net Profit after Tax	287	9%	-19%	353	11%
EPS (NTD)	0.36	-	-	0.45	-

Consolidated Balance Sheet

NTD Million	2023/12/31		2022/12/31	
Cash and Cash Equivalents	3,942	33%	4,295	36%
Accounts Receivable	788	7%	635	5%
Inventories	1,511	13%	1,189	10%
Property, Plant & Equipment	3,763	32%	3,843	32%
Other Current/Non-Current Assets	1,717	15%	1,949	17%
Total Assets	**11,721**	**100%**	**11,911**	**100%**
Financial Debt	32	0%	78	1%
Other Current Liabilities	697	6%	725	6%
Other Non-Current Liabilities	628	6%	658	5%
Total Liabilities	**1,357**	**12%**	**1,461**	**12%**
Total Shareholders' Equities	**10,364**	**88%**	**10,450**	**88%**

Consolidated Cash Flow Statement

NTD million	2023	2022	Dif.
From Operating Activities	**231**	**774**	**-543**
Depreciation & Amortization	461	439	22
From Investing Activities	**(233)**	**(253)**	**20**
Capital Expenditure	(285)	(250)	-35
From Financing Activities	**(341)**	**(315)**	**-26**
Effect of foreign exchange rate changes	**(10)**	**8**	**-18**
Net Change in Cash	**(353)**	**214**	**-567**
Beginning Balance	**4,295**	**4,081**	**214**
Ending Balance	**3,942**	**4,295**	**-353**



Q & A

Appendix
Company Overview

ScinoPharm at a Glance

- Est. 1997 in Taiwan with R&D/CGMP plants in Tainan and Changshu, China plus marketing forces in Tainan, Shanghai and Tokyo
- Specializes in providing R&D and CGMP manufacturing of APIs (cytotoxic/steroid) and injectable drug products
- 76 generic APIs in portfolio with 37 referred and approved ANDAs/NDAs*
  - 924 active DMFs worldwide with 68 US DMFs*
- 200+ contract projects with 12 approved/launched (10 NCEs) and 5 in phase 3 for NDA/MAA filing within 1-3 years*
- API plant certified by key international regulators - US FDA, EMA, EDQM, Australian TGA, Japanese PMDA, Korea KFDA, Mexico COFEPRIS and German Authority
- Injectable plant certified by US FDA and TFDA

*As of 2024/01/31

Brand Quality with Asian Advantages

www.scinopharm.com

1789 TT